1. Association of device surface and biomaterials with immunologic sensitization after mechanical support 
Isaac George, MD, Patrick Colley, BS, Mark J. Russo, MD, Timothy P. Martens, MD, Elizabeth Burke, MS, Mehmet C. Oz, MD, Mario C. Deng, MD, Donna M. Mancini, MD, Yoshifumi Naka, MD, PhD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 135, Issue 6, Pages e1 (June 2008)
DOI: /j.jtcvs
Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
A, Overall percentage of patients sensitized at any time during left ventricular assist device support by device type. Asterisk indicates P = .025 versus HeartMate I. HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey. B, Percentage of sensitized patients before transplant (P = .590). HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey.
The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs )
Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
A, Percentage of patients sensitized during first 3 months of left ventricular assist device (LVAD) support by device type. Asterisk indicates P < .001 versus HeartMate I at 1 month; dagger indicates P = .021 versus HeartMate I at 3 months. HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey. B, Mean peak panel reactive antibody (PRA) levels during first 3 months of left ventricular assist device (LVAD) support and before transplant by device type (HeartMate II or DeBakey vs HeartMate I, P = .09 at 3 months). HMI, HeartMate I; HMII-DB, HeartMate II or DeBakey. C, Acute rejection within first 9 months after transplant was increased after HeartMate I (HMI) support versus HeartMate II or DeBakey (HMII-DB) support when examining all patients undergoing transplant. Asterisk indicates P = .052 versus HeartMate I.
The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs )
Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions